COMPASS Pathways plc (NASDAQ:CMPS) Given Consensus Recommendation of "Buy" by Brokerages

Shares of COMPASS Pathways plc (NASDAQ:CMPS - Get Free Report) have received an average recommendation of "Buy" from the six analysts that are presently covering the company, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $20.20.

A number of analysts recently issued reports on CMPS shares. Cantor Fitzgerald reiterated an "overweight" rating on shares of COMPASS Pathways in a research note on Friday, March 28th. HC Wainwright reissued a "buy" rating and issued a $45.00 price target on shares of COMPASS Pathways in a report on Tuesday, March 4th. Stifel Nicolaus initiated coverage on shares of COMPASS Pathways in a report on Thursday, February 27th. They set a "buy" rating and a $11.00 target price on the stock. Canaccord Genuity Group cut their price target on shares of COMPASS Pathways from $23.00 to $15.00 and set a "buy" rating for the company in a report on Friday, February 28th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $18.00 price objective on shares of COMPASS Pathways in a research report on Wednesday, January 15th.

COMPASS Pathways Stock Performance

COMPASS Pathways stock traded down $0.08 during trading on Thursday, hitting $3.80. The stock had a trading volume of 98,006 shares, compared to its average volume of 786,939. The stock's 50 day moving average is $3.34 and its two-hundred day moving average is $4.16. COMPASS Pathways has a 1 year low of $2.49 and a 1 year high of $9.63. The stock has a market cap of $352.16 million, a price-to-earnings ratio of -1.72 and a beta of 2.34. The company has a quick ratio of 8.91, a current ratio of 8.91 and a debt-to-equity ratio of 0.15.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.63) earnings per share for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.01). As a group, analysts predict that COMPASS Pathways will post -2.33 EPS for the current year.

Hedge Funds Weigh In On COMPASS Pathways

A number of large investors have recently modified their holdings of the company. GAMMA Investing LLC lifted its position in COMPASS Pathways by 93.6% in the first quarter. GAMMA Investing LLC now owns 10,349 shares of the company's stock valued at $30,000 after purchasing an additional 5,003 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in COMPASS Pathways during the fourth quarter worth about $41,000. Flagship Harbor Advisors LLC increased its holdings in shares of COMPASS Pathways by 27.7% during the first quarter. Flagship Harbor Advisors LLC now owns 14,446 shares of the company's stock valued at $41,000 after acquiring an additional 3,134 shares in the last quarter. Wealthfront Advisers LLC purchased a new position in COMPASS Pathways in the 4th quarter worth approximately $43,000. Finally, OLD National Bancorp IN purchased a new stake in shares of COMPASS Pathways during the 1st quarter valued at about $45,000. 46.19% of the stock is owned by hedge funds and other institutional investors.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.